Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105443 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
A Phase 3 study of Carcinoma, Hepatocellular, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 602
- Enrollment target
- 20
- Study locations
NCT00105443 is a Phase 3 study of Carcinoma, Hepatocellular that has completed, run by Bayer. The registered enrollment target is 602 participants, roughly in line with the 590-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target. The trial reports 20 study locations across 9 states.
The verdict
NCT00105443, a Phase 3 study of Carcinoma, Hepatocellular, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 602 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find out if sorafenib has any effect on patient reported outcomes. Find out if sorafenib prevents the growth of or shrinks liver tumors and/or their metastases. Determine the pharmacokinetics (PK) in patients with liver cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sorafenib (Nexavar, BAY43-9006)
Study Locations (20)
California
- - Los Angeles
- - Los Angeles
- - Orange
- - San Francisco
- - Stanford
Florida
- - Gainesville
- - Miami
- - Tampa
Arizona
- - Phoenix
- - Tucson
Connecticut
- - Farmington
- - New Haven
Georgia
- - Atlanta
- - Atlanta
Illinois
- - Chicago
- - Chicago
Michigan
- - Ann Arbor
- - Detroit
Kentucky
- - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105443
The ClinicalTrials.gov registry entry for NCT00105443 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 602 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 590-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00105443 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00105443 about?
NCT00105443 is a clinical study titled "A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma". The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find out if sorafenib has any effect on patient reported outcomes. Find out if sorafenib prevents the growth of or shrinks liver tumors and/or their metastases. Determine the pharmacokinetics (PK) in patients wit...
What is the current status of trial NCT00105443?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 602 participants. The study started on 2005-03. Estimated completion is 2008-11.
What conditions does trial NCT00105443 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT00105443?
The interventions under investigation include: Placebo (DRUG), Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00105443?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00105443 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
COMPLETED · Phase 3
-
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
COMPLETED · Phase 3
-
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
COMPLETED · Phase 3
-
90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.